The global immunotherapy drugs market is expected to grow at a CAGR of 16.2% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of chronic diseases and rising demand for immunotherapy drugs in emerging economies.
The global immunotherapy drugs market is segmented on the basis of type, application, and region. On the basis of type, it is classified into adult vaccines, checkpoint inhibitors, and interferons alpha. On the basis of application, it includes cancer treatment; autoimmune diseases; and infectious diseases treatment. On the basis of region, it covers North America (US, Canada), Latin America (Mexico), Europe (Germany), Asia Pacific (China) and Middle East & Africa (Saudi Arabia).
Some Of The Growth Factors Of This Market:
- The increasing prevalence of cancer and other chronic diseases is driving the growth of the immunotherapy drugs market.
- Increasing research and development activities in this field are also contributing to the growth of this market.
- Increasing awareness about immunotherapy drugs among patients, physicians, and payers is also driving the growth of this market.
- The high cost associated with these treatments may hamper the growth rate.
- Immunotherapy drugs are not yet approved by FDA for all types of cancers.
Industry Growth Insights published a new data on “Immunotherapy Drugs Market”. The research report is titled “Immunotherapy Drugs Market research by Types (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), By Applications (Cancer, Autoimmune Diseases, Infectious Diseases), By Players/Companies ELI Lilly and Company, Merck & Co., Inc, F. Hoffmann-La Roche AG, Novartis International AG, Johnson & Johnson, Glaxosmithkline PLC, Amgen Inc., Abbvie, Astrazeneca, Bristol-Myers Squibb”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Immunotherapy Drugs Market Research Report
By Type
Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha
By Application
Cancer, Autoimmune Diseases, Infectious Diseases
By Companies
ELI Lilly and Company, Merck & Co., Inc, F. Hoffmann-La Roche AG, Novartis International AG, Johnson & Johnson, Glaxosmithkline PLC, Amgen Inc., Abbvie, Astrazeneca, Bristol-Myers Squibb
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Immunotherapy Drugs Market Report Segments:
The global Immunotherapy Drugs market is segmented on the basis of:
Types
Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Autoimmune Diseases, Infectious Diseases
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ELI Lilly and Company
- Merck & Co., Inc
- F. Hoffmann-La Roche AG
- Novartis International AG
- Johnson & Johnson
- Glaxosmithkline PLC
- Amgen Inc.
- Abbvie
- Astrazeneca
- Bristol-Myers Squibb
Highlights of The Immunotherapy Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Adult Vaccines
- Checkpoint Inhibitors
- Interferons Alpha
- By Application:
- Cancer
- Autoimmune Diseases
- Infectious Diseases
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Immunotherapy Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Immunotherapy drugs are medications that help the body's immune system fight cancer. Immunotherapy drugs can be used in combination with other treatments, such as radiation and chemotherapy, to help improve the chances of successful cancer treatment.
Some of the key players operating in the immunotherapy drugs market are ELI Lilly and Company, Merck & Co., Inc, F. Hoffmann-La Roche AG, Novartis International AG, Johnson & Johnson, Glaxosmithkline PLC, Amgen Inc., Abbvie, Astrazeneca, Bristol-Myers Squibb.
The immunotherapy drugs market is expected to register a CAGR of 16.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Immunotherapy Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Immunotherapy Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Immunotherapy Drugs Market - Supply Chain
4.5. Global Immunotherapy Drugs Market Forecast
4.5.1. Immunotherapy Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Immunotherapy Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Immunotherapy Drugs Market Absolute $ Opportunity
5. Global Immunotherapy Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Immunotherapy Drugs Market Size and Volume Forecast by Type
5.3.1. Adult Vaccines
5.3.2. Checkpoint Inhibitors
5.3.3. Interferons Alpha
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Immunotherapy Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Immunotherapy Drugs Market Size and Volume Forecast by Application
6.3.1. Cancer
6.3.2. Autoimmune Diseases
6.3.3. Infectious Diseases
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Immunotherapy Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Immunotherapy Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Immunotherapy Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Immunotherapy Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Immunotherapy Drugs Demand Share Forecast, 2019-2029
9. North America Immunotherapy Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Immunotherapy Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Immunotherapy Drugs Market Size and Volume Forecast by Application
9.4.1. Cancer
9.4.2. Autoimmune Diseases
9.4.3. Infectious Diseases
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Immunotherapy Drugs Market Size and Volume Forecast by Type
9.7.1. Adult Vaccines
9.7.2. Checkpoint Inhibitors
9.7.3. Interferons Alpha
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Immunotherapy Drugs Demand Share Forecast, 2019-2029
10. Latin America Immunotherapy Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Immunotherapy Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Immunotherapy Drugs Market Size and Volume Forecast by Application
10.4.1. Cancer
10.4.2. Autoimmune Diseases
10.4.3. Infectious Diseases
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Immunotherapy Drugs Market Size and Volume Forecast by Type
10.7.1. Adult Vaccines
10.7.2. Checkpoint Inhibitors
10.7.3. Interferons Alpha
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Immunotherapy Drugs Demand Share Forecast, 2019-2029
11. Europe Immunotherapy Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Immunotherapy Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Immunotherapy Drugs Market Size and Volume Forecast by Application
11.4.1. Cancer
11.4.2. Autoimmune Diseases
11.4.3. Infectious Diseases
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Immunotherapy Drugs Market Size and Volume Forecast by Type
11.7.1. Adult Vaccines
11.7.2. Checkpoint Inhibitors
11.7.3. Interferons Alpha
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Immunotherapy Drugs Demand Share, 2019-2029
12. Asia Pacific Immunotherapy Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Immunotherapy Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Immunotherapy Drugs Market Size and Volume Forecast by Application
12.4.1. Cancer
12.4.2. Autoimmune Diseases
12.4.3. Infectious Diseases
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Immunotherapy Drugs Market Size and Volume Forecast by Type
12.7.1. Adult Vaccines
12.7.2. Checkpoint Inhibitors
12.7.3. Interferons Alpha
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Immunotherapy Drugs Demand Share, 2019-2029
13. Middle East & Africa Immunotherapy Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Immunotherapy Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Immunotherapy Drugs Market Size and Volume Forecast by Application
13.4.1. Cancer
13.4.2. Autoimmune Diseases
13.4.3. Infectious Diseases
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Immunotherapy Drugs Market Size and Volume Forecast by Type
13.7.1. Adult Vaccines
13.7.2. Checkpoint Inhibitors
13.7.3. Interferons Alpha
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Immunotherapy Drugs Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Immunotherapy Drugs Market: Market Share Analysis
14.2. Immunotherapy Drugs Distributors and Customers
14.3. Immunotherapy Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. ELI Lilly and Company
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck & Co., Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. F. Hoffmann-La Roche AG
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis International AG
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Johnson & Johnson
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Glaxosmithkline PLC
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Amgen Inc.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Abbvie
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Astrazeneca
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Bristol-Myers Squibb
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
